JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
146.45
-1.28 (-0.87%)
At close: 4:01PM EST

145.85 -0.59 (-0.40%)
Pre-Market: 5:04AM EST

Stock chart is not supported by your current browser
Previous Close147.73
Open147.50
Bid146.55 x 900
Ask146.95 x 1000
Day's Range146.35 - 148.75
52 Week Range118.62 - 148.75
Volume8,937,990
Avg. Volume6,679,672
Market Cap392.776B
Beta (3Y Monthly)0.31
PE Ratio (TTM)257.38
EPS (TTM)0.57
Earnings DateJan 22, 2019
Forward Dividend & Yield3.60 (2.47%)
Ex-Dividend Date2018-11-26
1y Target Est148.11
Trade prices are not sourced from all markets
  • Can Deal Interest Help Tesaro Recover?
    Motley Fool27 minutes ago

    Can Deal Interest Help Tesaro Recover?

    This isn't the first time this biotech has explored a sale, but conditions are a little different now.

  • ACCESSWIRE2 hours ago

    Today's Research Reports on Trending Tickers: Johnson & Johnson and Merck & Co.

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / U.S. markets plunged on Tuesday as FAANG (Facebooks, Amazon, Apple, Netflix and Google) stocks entered into bear market territory, pressuring the tech sector ...

  • Bloomberg4 hours ago

    Capitalism Is Working in the U.S.

    It remains the most referenced guide to prosperity because of its moral force: Smith said the freest markets are led by an invisible hand benefiting everyone, not just the individuals and companies motivated by their own profit. American free enterprise is achieving the greatest growth in the developed world, posting annual gross domestic product gains since 2009. Within just eight years of the global financial crisis, the U.S. was the only non-emerging-market economy with record GDP.

  • Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
    Zacks17 hours ago

    Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

    Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

  • Nasdaq Slides More Than 3% As These Dow Blue Chips Buck The Broad Sell-Off
    Investor's Business Daily2 days ago

    Nasdaq Slides More Than 3% As These Dow Blue Chips Buck The Broad Sell-Off

    The Nasdaq got smacked with its biggest single-session loss in more than three weeks and nearly faced a test of the psychologically important 7000 level.

  • Merck’s Stock Price Has Increased ~34% in 2018
    Market Realist20 hours ago

    Merck’s Stock Price Has Increased ~34% in 2018

    On November 16, Merck’s (MRK) stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15. Merck’s stock price grew from $56.79 when the market opened on January 2 to $76.06 when the market closed on November 16, which representing ~34% year-to-date growth. On November 16, Merck hit its 52-week high of $76.25.

  • TheStreet.com20 hours ago

    Here's What's Actually Working as the Market Sells Off: Charts

    The broad market is correcting deeply for a second straight trading session, with the big S&P 500 gapping down to re-test the lows set in October -- during the worst month for stocks since 2011. Tuesday shares are managing to hold up much better than the broad market.

  • 5 Dow Stocks to Sell (And 2 to Buy)
    Kiplinger21 hours ago

    5 Dow Stocks to Sell (And 2 to Buy)

    Most stocks have been thoroughly shaken and stirred since early October, and a long-overdue corrective move finally took shape. Not even the bluest of the blue chips have been immune. The Dow Jones Industrial Average still is off its record high from a couple months ago, and several Dow stocks still are vulnerable to more selling. The initial shellshock has started to fade, however, the smoke is clearing and some stocks are recovering. Smart investors are now weighing the impact and searching for opportunities. Some Dow Jones stocks may have more downside to dish out, but a handful of these iconic names are looking oversold, undervalued and ripe for a rebound sooner than later. Remember: Corporate earnings have never been better, and consumer confidence is as high as it's been in years. Clearly something is going right. Here's a look at five Dow stocks that may have more ground to give up before they hit bottom, and two industrial-average components that may already be buys at current prices. But a note: Most of these "stocks to sell" are merely in short-term trouble. A sizable pullback from any of them could ultimately turn into a buying opportunity. SEE ALSO: 12 Vulnerable Stocks to Watch on Market-Wide Weakness

  • GuruFocus.com22 hours ago

    5 Companies Hit 52-Week Highs

    Recently, multiple companies have managed to achieve yearly highs

  • Benzingayesterday

    The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks2 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed at $147.82 in the latest trading session, marking a +1.25% move from the prior day.

  • TheStreet.com2 days ago

    Bulls Stampeded by Bears as FAANG Stocks Get Trampled

    continues to struggle with management issues and the shortfall in Apple orders drove it to a new recent low. With those two stocks under heavy pressure there weren't any buyers rushing to buy the other big-cap technology names. Retail, biotechnology, software, semiconductors and most all of the sectors that lead in a strong market were down Monday.

  • TheStreet.com2 days ago

    Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

    The major indices continue to see extreme selling pressure. Breadth is running about 1,750 gainers to 5,350 decliners and new 12-month lows are over 300. There is a steady diet of bad news and no immediate technical support until the lows of October are retested.

  • TheStreet.com2 days ago

    Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

    "PFE's oncology assets will make up 13% of its total 2018 sales, according to FactSet, and they will accelerate PFE's sales growth for the foreseeable future, but these drugs are underappreciated," Cantor Fitzgerald analyst Louise Chen wrote on Sunday. The cancer drug market is expected to accelerate quickly in the coming years, growing from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020, according to Allied Market Research.

  • J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment
    Zacks2 days ago

    J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment

    Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.

  • Baxter International: Analysts Remain Bullish on the Stock
    Market Realist2 days ago

    Baxter International: Analysts Remain Bullish on the Stock

    In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.

  • Yacktman Asset Management Sells Oracle, Johnson & Johnson
    GuruFocus.com3 days ago

    Yacktman Asset Management Sells Oracle, Johnson & Johnson

    Yacktman Asset Management (Trades, Portfolio) Co. sold shares in the following stocks during the third quarter. Warning! GuruFocus has detected 6 Warning Signs with ORCL. The guru trimmed its Oracle Corp. (ORCL) position by 5.77%.

  • Better Buy: Abbott Laboratories vs. Johnson & Johnson
    Motley Fool3 days ago

    Better Buy: Abbott Laboratories vs. Johnson & Johnson

    Which big healthcare stock is the better pick for investors now?

  • GuruFocus.com4 days ago

    Johnson & Johnson (JNJ) Chairman, CEO Alex Gorsky Sold $38.6 million of Shares

    Chairman, CEO of Johnson & Johnson (NYSE:JNJ) Alex Gorsky sold 264,465 shares of JNJ on 11/16/2018 at an average price of $145.96 a share.

  • How Bausch + Lomb/International Performed
    Market Realist5 days ago

    How Bausch + Lomb/International Performed

    Bausch + Lomb/International is a wholly owned subsidiary of Bausch Health Companies (BHC). Bausch + Lomb/International generated revenues of $1.1 billion in the third quarter of this year compared to $1.2 billion in the third quarter of 2017, reflecting a ~7% YoY decline. However, Bausch + Lomb/International witnessed ~3% organic revenue growth.

  • Analyzing Baxter International’s Operational Performance
    Market Realist5 days ago

    Analyzing Baxter International’s Operational Performance

    Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.

  • Baxter International: Why Investors Are Interested
    Market Realist5 days ago

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.

  • New jury fails to reach verdict in J&J South Carolina talc cancer trial
    Reuters5 days ago

    New jury fails to reach verdict in J&J South Carolina talc cancer trial

    The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that centre around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.

  • PR Newswire5 days ago

    ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'

    First-of-its-kind contact lens corrects vision and adapts to changing light conditions JACKSONVILLE, Fla. , Nov. 16, 2018 /PRNewswire/ -- TIME has selected ACUVUE OASYS with Transitions Light Intelligent ...

  • New jury fails to reach verdict in J&J South Carolina talc cancer trial
    Reuters5 days ago

    New jury fails to reach verdict in J&J South Carolina talc cancer trial

    The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that center around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.